Sight Sciences Q2 Earnings Call Highlights

Second-quarter revenue rose 20% year over year to $23.4 million , driven by 8% growth in interventional glaucoma revenue and nearly doubled interventional dry eye revenue.

Operating expenses, net loss and adjusted cash use all declined substantially.

Sight Sciences raised its 2026 revenue outlook to $88 million–$92 million and increased interventional dry eye guidance to $9 million–$11 million, while lowering adjusted operating expense guidance to $92 million–$94 million.

TearCare adoption and reimbursement access expanded, while glaucoma growth benefited from higher OMNI utilization, broader payer coverage and the planned launch of next-generation OMNI Ultra technology.

Second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Total revenue for the quarter ended June 30 was $23.4 million, up from the prior-year period and representing the company’s strongest quarterly growth rate in three years, Chief Financial Officer Jim Rodberg said.

Interventional glaucoma revenue rose 8% to $20.7 million, while interventional dry eye revenue reached a record $2.7 million, nearly doubling from $1.4 million in the first quarter.

We delivered a strong second quarter with revenue growing 20% year-over-year,” Co-founder and Chief Executive Officer Paul Badawi said, citing growth across both business segments and improved operating results.

The company’s interventional dry eye business benefited from increasing adoption of its TearCare treatment platform in reimbursed markets.

Ordering accounts increased to 176 during the second quarter from 96 in the first quarter, and those accounts purchased more than 3,000 SmartLids, more than twice the prior-quarter volume. Average utilization increased to approximately 18 SmartLids per active account, from 16 in the first quarter.

Badawi said roughly two-thirds of SmartLids volume came from accounts that also use Sight Sciences’ interventional glaucoma products, with those overlapping accounts showing higher utilization than dry eye-only customers.

During the quarter, the company added approximately 4.1 million patient lives with access to appropriate reimbursement, bringing the total to approximately 14.5 million from 10.4 million.

Chief Operating Officer Ali Bauerlein said some Medicare Advantage plans added fee schedules to provider portals during the quarter, and providers have begun submitting claims and receiving payment.

However, Bauerlein said the contribution from those payer developments to second-quarter results was “very modest,” as providers were still testing claims submissions. The company expects the effect to grow during the second half of 2026.

Sight Sciences increased its full-year interventional dry eye revenue guidance to $9 million to $11 million, up from a prior range of $6 million to $8 million. Management said the updated outlook does not assume additional market-access wins, although it continues discussions with Medicare Administrative Contractors and commercial payers regarding coverage policies and fee schedules.

Bauerlein said the company’s payer discussions are supported by clinical data from the SAHARA trial and health economic data that management believes demonstrate benefits relative to prescription eye drops. She cautioned that payer decisions and their timing remain outside the company’s control.

Interventional glaucoma revenue rises as OMNI account base expands Interventional...